Author

Y.-C. Juang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. W. Partridge· 2 shared S. Ng· 2 shared A. Chandramohan· 1 shared A. Sadruddin· 1 shared A. Stoeck· 1 shared B. Henry· 1 shared C. J. Brown· 1 shared C. S. Verma· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. W. Partridge

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 26, 2020

bioPROTACs establish RAS as a degradable target and provide novel RAS biology insights

S. Lim, R. Khoo, Y.-C. Juang…·A. W. Partridge

The paper demonstrates that RAS proteins can be degraded using bioPROTACs and provides insights into the functional consequences of RAS degradation and mutant susceptibility.

DOI 10.1101/2020.06.26.174565

humanproteomics

𝕏 PostBluesky

BiochemistrybioRxivMay 21, 2019

De-risking drug discovery of intracellular targeting peptides: screening strategies to eliminate false-positive hits

S. Ng, Y.-C. Juang, A. Chandramohan…·D. P. Lane

This paper identifies false-positive peptide inhibitors of KRas using orthogonal assays and cellular screens, highlighting the need for rigorous validation in drug discovery.

DOI 10.1021/acsmedchemlett.0c00022

humanproteomics

𝕏 PostBluesky